Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Amarantus BioScience Reports Positive Data in Neuroprotection Animal Models of Parkinson’s Disease

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
Company’s proprietary therapeutic appears to protect key dopamine-producing brain function.

Amarantus BioScience, Inc. reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson’s disease. The data show that MANF protects the integrity of dopamine producing neurites in the striatum.

“Our scientists are excited by this data, which not only demonstrates the efficacy of MANF, but its superiority to GDNF, as well,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. “Based on this study, we believe MANF plays a role in maintaining brain connectivity, specifically the dopaminergic system of the basal ganglia network, which reinforces the potential of MANF as a disease-modifying treatment for Parkinson’s.”

In the neuroprotection study, MANF was delivered into the substantia nigra shortly before injection of the toxin 6-OHDA into the striatum. Four weeks later the animals were sacrificed and the density of dopaminergic neuron projections in the striatum was determined. The protection of neuron health, as measured by the density of neurite terminals, was evident in all three areas of the striatum examined.

The effects of a single MANF treatment were evident after four weeks, indicating the effects of MANF protection are sustained. Furthermore, the highest level of neurite density was found at the highest dosage of MANF. Importantly, the neurite density measured under treatment with MANF was statistically significantly better than shown for both vehicle control and a standard dosage of Glial cell-Derived Neurotrophic Factor (GDNF). GDNF is currently in clinical trials for Parkinson’s disease and considered the current benchmark in the field. The data summarized here suggests that MANF may have advantages over GDNF for the clinical treatment of Parkinson’s disease.

“The data on MANF continues to return more favorable results than other molecules currently in clinical development as disease-modifying treatments for Parkinson’s disease,” said Dr. Joseph Rubinfeld, Amgen co-founder and current member of the Company’s Board of Advisors. “We intend to conduct select additional experiments to understand why this appears to be the case while we continue the IND-enabling studies that have already been initiated. We believe these additional data points will further distinguish MANF from competitors in the field, and will deliver significant value in the near-term.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amarantus Completes Acquisition of ESS from Lonza
Amarantus now has full ownership of Cutanogen Corporation, which has exclusive worldwide license to orphan drug product candidate Engineered Skin Substitute (ESS).
Friday, July 24, 2015
Scientific News
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!